Polpharma SA Pharmaceutical Works signed an agreement to acquire Production Rights to Lakcid, Lakcid Forte & Lakcid L Brands from BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek Spólka Akcyjna (WSE:BML) for PLN 17 million on November 1, 2017. As per the terms of the deal, BIOMED-LUBLIN will sell 100% of production rights and the umbrella brand of Lakcid, Lakcid Forte and Lakcid L. The deal also includes the license to sell the active ingredient on international markets. The price will be paid within 14 days from signing the agreement. Under the terms of the agreement, BIOMED-LUBLIN will produce products for Polpharma SA Pharmaceutical Works for at least 5 years and the contract may be renewed for another 2-year period. Biomed Lublin will use the proceeds to pay the first installment of liabilities to PARP amounting to nearly PLN 11.3 million plus interest. The remaining PLN 5.7 million will be used for faster-than-planned investment projects related to modernization and capacity building on Onko-BCG and Distreptaze lines, increased working capital requirements resulting from agreements signed with Polpharma and investments.